Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
25.95
-0.39 (-1.48%)
Mar 6, 2026, 4:00 PM EST - Market closed
Centessa Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 15 | - | 6.85 | - | - | - | Upgrade
|
| Gross Profit | 15 | - | 6.85 | - | - | - | Upgrade
|
| Selling, General & Admin | 50.18 | 50.81 | 53.73 | 55.2 | 43.01 | 1.14 | Upgrade
|
| Research & Development | 178.62 | 150.24 | 124.41 | 155.08 | 96.32 | 9.3 | Upgrade
|
| Operating Expenses | 228.8 | 201.06 | 178.14 | 210.28 | 139.33 | 10.44 | Upgrade
|
| Operating Income | -213.8 | -201.06 | -171.28 | -210.28 | -139.33 | -10.44 | Upgrade
|
| Interest Expense | -11.13 | -10.09 | -9.91 | -7.28 | -2.55 | -0.38 | Upgrade
|
| Interest & Investment Income | 20.88 | 14.02 | 10.48 | 0.24 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -1.3 | -1.8 | 0.8 | -2.8 | -3.6 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.14 | 0.11 | -0.33 | -0.76 | -0.77 | 0.16 | Upgrade
|
| EBT Excluding Unusual Items | -205.21 | -198.82 | -170.24 | -220.87 | -146.25 | -10.66 | Upgrade
|
| Other Unusual Items | -34.1 | -34.1 | -5.9 | 3.92 | -15.08 | - | Upgrade
|
| Pretax Income | -239.31 | -232.91 | -176.14 | -216.95 | -381.79 | -10.66 | Upgrade
|
| Income Tax Expense | 3.39 | 2.84 | -25.06 | -0.75 | 0.11 | - | Upgrade
|
| Net Income | -242.7 | -235.76 | -151.09 | -216.21 | -381.9 | -10.66 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | -0.83 | - | Upgrade
|
| Net Income to Common | -242.7 | -235.76 | -151.09 | -216.21 | -381.07 | -10.66 | Upgrade
|
| Shares Outstanding (Basic) | 133 | 114 | 96 | 93 | 75 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 133 | 114 | 96 | 93 | 75 | 15 | Upgrade
|
| Shares Change (YoY) | 25.82% | 19.02% | 2.97% | 24.26% | 401.11% | - | Upgrade
|
| EPS (Basic) | -1.82 | -2.06 | -1.57 | -2.31 | -5.07 | -0.71 | Upgrade
|
| EPS (Diluted) | -1.82 | -2.06 | -1.57 | -2.31 | -5.07 | -0.71 | Upgrade
|
| Free Cash Flow | -181.17 | -142.09 | -160.51 | -201.68 | -136.34 | -10.63 | Upgrade
|
| Free Cash Flow Per Share | -1.36 | -1.24 | -1.67 | -2.16 | -1.81 | -0.71 | Upgrade
|
| Gross Margin | 100.00% | - | 100.00% | - | - | - | Upgrade
|
| Operating Margin | -1425.33% | - | -2499.39% | - | - | - | Upgrade
|
| Profit Margin | -1617.99% | - | -2204.66% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -1207.80% | - | -2342.20% | - | - | - | Upgrade
|
| EBITDA | -213.49 | -200.71 | -170.97 | -210.15 | -139.3 | -10.43 | Upgrade
|
| D&A For EBITDA | 0.31 | 0.34 | 0.31 | 0.13 | 0.03 | 0.01 | Upgrade
|
| EBIT | -213.8 | -201.06 | -171.28 | -210.28 | -139.33 | -10.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.